Monday, June 22, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 208 of 1,261

  1. US 11590132

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  2. US 11590223

    Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  3. US 11590229

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  4. US 11591341

    Bicyclic and tricyclic compounds

    Aligos Therapeutics, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  5. US 11591336

    Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors

    Relay Therapeutics, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  6. US 11591304

    SLC26A3 inhibitors and use thereof

    The Regents of the University of California · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  7. US 11590116

    Substituted pyridines and methods of use

    Theravance Biopharma R&D IP, LLC · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  8. US 11591381

    Gene-edited natural killer cells

    CRISPR THERAPEUTICS AG · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  9. US 11583578

    Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery

    The Government of the United States, as represented by the Secretary of the Army · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  10. US 11583541

    Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  11. US 11582956

    Recombinant adenovirus-based interferon biotherapeutics in swine

    The United States of America, as represented by the Secretary of Agriculture · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  12. US 11583584

    Stable protein compositions and methods of their use

    Coherus BioSciences, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  13. US 11583542

    Compositions of bile acids and phenylbutyrate compounds

    Amylyx Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  14. US 11583529

    Treatment of inflammatory disorders

    Aldeyra Therapeutics, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  15. US 11583489

    Flushable wipe and method of forming the same

    First Quality Tissue, LLC · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  16. US 11583548

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  17. US 11584933

    RNA interference in ocular indications

    Phio Pharmaceuticals Corp. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  18. US 11584966

    Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  19. US 11584780

    Adeno-associated virus capsid proteins

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  20. US 11584736

    Heterocyclic P2Y14 receptor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  21. US 11584758

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  22. US 11584737

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  23. US 11584733

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  24. US 11584735

    Solid forms of a plasma kallikrein inhibitor and salts thereof

    KalVista Pharmaceuticals Limited · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.